Top

Osteoporosis International

Published in:

01-11-2006 | Review

Bone fragility in men - where are we?

Authors: E. Seeman, G. Bianchi, S. Khosla, J. A. Kanis, E. Orwoll

Published in: Osteoporosis International | Issue 11/2006

Abstract

Introduction

This is a summary of several aspects of the epidemiology, pathogenesis and treatment arising directly and indirectly from the proceedings of the Third International Osteoporosis in Men meeting held in Genoa in May 2005. Advances in the study of bone fragility in men have taken place, but many challenges remain.

Observations

Although the epidemiology of hip fractures is well documented, the epidemiology of other non-vertebral fractures is less well defined even though these fractures contribute substantially to the global burden of fractures in men. The epidemiology of vertebral fragility fractures is derived mostly from cross sectional data. The comparable prevalence of vertebral fractures in men and women is likely to be misleading because of traumatic vertebral fractures that arise in young men. Prospective studies are needed to define the proportion of these fractures that are traumatic. After the age of 50 years, the incidence of vertebral fractures in men is about one third to one half of that in women. As in women, most vertebral and non-vertebral fragility fractures occur in persons without osteoporosis. Identifying these individuals is an unmet challenge. The absolute risk for fractures appears no different by sex in men and women of the same age and bone mineral density (BMD) so that the diagnostic threshold for osteoporosis in women can be used in men. Fracture risk varies around the world and is unlikely to be explained solely by variations in BMD, though there are few data comparing men and women of different races. Both the notion that men lose less bone than women from the endosteal envelope and that they gain more on the periosteal envelope during advancing age needs reassessment as recent evidence challenges these observations. Sex differences in the net gain and loss from these surfaces are likely to be site specific, and research is needed to specify this heterogeneity and the reasons for it. The independent and co-dependent effects of sex hormones and the growth hormone/insulin like growth factor 1 axis on periosteal and endosteal modeling and remodeling during growth as well as ageing are poorly defined. The anti-fracture efficacy and safety of androgens and other agents remain incompletely investigated in men.

Conclusion

A great deal of research is needed to advance our understanding of bone fragility in men.

Cooper C, Dennison EM, Leufkens HGM, Bishop N, Van Staa TP (2004) Epidemiology of childhood fractures in Britain: a study using the general practice research database. J Bone Miner Res 19:1976–1981PubMedCrossRef

Johnell O, Kanis JA, Jonsson B, Oden A, Johansson H, De Laet C (2005) The burden of hospitalised fractures in Sweden. Osteoporos Int 16:222–228PubMedCrossRef

Jiang HX, Majumdar SR, Dick DA, Moreau M, Raso J, Otto DD, Johnston DWC (2005) Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures. J Bone Miner Res 20:494–500PubMedCrossRef

Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468–473PubMedCrossRef

Khosla S, Lufkin EG, Hodgson SF, Fitzpatrick LA, Melton LJ (1994) Epidemiology and clinical-features of osteoporosis in young individuals. Bone 15:551–555PubMedCrossRef

Orwoll ES, Klein RF (1995) Osteoporosis in men. Endocr Rev 16:87–116PubMedCrossRef

Schuit SCE, van der Klift M, Weel AEAM, de Laet CEDH, Burger H, Seeman E, Hofman A, Uitterlinden AG, van Leeuwen JPTM, Pols HAP (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34:195–202PubMedCrossRef

Szulc P, Munoz F, Duboeuf F, Marchand F, Delmas PD (2005) Bone mineral density predicts osteoporotic fractures in elderly men: the MINOS study. Osteoporos Int 16:1184–1192PubMedCrossRef

Sornay-Rendu E, Munoz F, Garnero P, Duboeuf F, Pierre D, Delmas PDD (2005) The identification of osteopenic women at high risk of fracture: the OFELY Study. J Bone Miner Res 20:1929–1943PubMedCrossRef

10.

Kanis JA, Johnell O, Oden A et al (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12:989–995PubMedCrossRef

11.

Kanis JA, Oden A, Johnell O et al (2001) The burden of osteoporotic fractures: a method of setting intervention thresholds. Osteoporos Int 12:417–427PubMedCrossRef

12.

Kanis JA, Johnell O, Oden A et al (2005) Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos Int 16:6–14PubMedCrossRef

13.

Kanis JA, Borgstrom F, Zethraeus Z et al (2005) Intervention thresholds for osteoporosis in men and women. Bone 36:22–32PubMedCrossRef

14.

Duan Y, Turner CH, Kim BT, Seeman E (2001) Sexual dimorphism in vertebral fragility is more the result of gender differences in age-related bone gain than bone loss. J Bone Miner Res 16:2267–2274PubMedCrossRef

15.

Duan Y, Beck TJ, Wang X-F, Seeman E (2003) Structural and biomechanical basis of sexual dimorphism in femoral neck fragility has its origins in growth and aging. J Bone Miner Res 18:1766–1774PubMedCrossRef

16.

Wang XF, Duan Y, Beck T, Seeman ER (2005) Varying contributions of growth and ageing to racial and sex differences in femoral neck structure and strength in old age. Bone 36:978–986PubMedCrossRef

17.

Seeman E (2003) Periosteal bone formation - a neglected determinant of bone strength. New Eng J Med 349:320–323PubMedCrossRef

18.

Ahlborg HG Johnell O, Turner CH, Rannevik G, Karlsson MK (2003) Bone loss and bone size after the menopause. N Engl J Med 349:327–334PubMedCrossRef

19.

Ruff CB, Trinkaus E, Walker A, Larsen CS (1993) Postcranial robusticity in Homo. 1: temporal trends and mechanical interpretation. Am J Phys Anthropol 91:21–53PubMedCrossRef

20.

Balena R, Shih M-S, Parfitt (1992) Bone resorption and formation on the periosteal envelope of the ilium: a histomorphometric study in healthy women. J Bone Miner Res 7:1475–1482PubMedCrossRef

21.

Riggs BL, Melton LJ III, Robb RA, Camp JJ, Atkinson EJ, Peterson JM, Rouleau PA, McCollough CH, Bouxsein ML, Khosla S (2004) A population-based study of age and sex differences in bone volumetric density, size, geometry and structure at different skeletal sites. J Bone Miner Res 19:1945–1954PubMedCrossRef

22.

Khosla S, Riggs BL, Atkinson EJ, Oberg AL, McDaniel LJ, Holets M, Peterson JM, Melton LJ 3rd (2006) Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J Bone Miner Res 21:124–131PubMedCrossRef

23.

Aaron JE, Makins NB, Sagreiy K (1987) The microanatomy of trabecular bone loss in normal aging men and women. Clin Orth RR 215:260–271

24.

Araujo AB, O’Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, McKinlay JB (2004) Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts male aging study. J Clin Endocrinol Metab 89:5920–5926PubMedCrossRef

25.

Bouillon R, Bex M, Vanderschueren D, Boonen S (2004) Estrogens are essential for male pubertal periosteal bone expansion. J Clin Endocrinol Metab 89:6025–6029PubMedCrossRef

26.

Khosla S, Melton LJ, Riggs BL (2002) Estrogen and the male skeleton. J Clin Endocrinol Metab 87:1443–1450PubMedCrossRef

27.

Khosla S, Melton LJ, Atkinson EJ, O’Fallon WM (2001) Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men. J Clin Endocrinol Metab 86:3555–3561PubMedCrossRef

28.

Khosla S, Riggs BL, Robb RA, Camp JJ, Achenbach SJ, Oberg AL, Rouleau PA, Melton LJ III (2005) Relationship of volumetric bone density and structural parameters at different skeletal sites to sex steroid levels in men. J Clin Endocrinol Metab 90:5096–5103PubMedCrossRef

29.

Orwoll ES (2003) Toward an expanded understanding of the role of the periosteum in skeletal helath. J Bone Miner Res 18:949–954PubMedCrossRef

30.

Sims NA, Dupont S, Krust A, Clement-LaCroix P, Minet D, Resche-Rigon M, Gaillard Kelly M, Baron R (2002) Deletion of estrogen receptors reveals a regulatory role for estrogen receptors beta in bone remodeling in females but not in males. Bone 30:18–25PubMedCrossRef

31.

Sims NA, Clement-Lacroix P, Minet D, Fraslon-Vanhulle C, Gaillard-Kelly M, Resche-Rigon M, Baron R (2003) A functional androgen receptor is not sufficient to allow estradiol to protect bone after gonadectomy in estradiol receptor-deficient mice. J Clin Invest 111:1319–1327PubMedCrossRef

32.

Szulc P, Garnero P, Marchand F, Duboeuf F, Delmas PD (2005) Biochemical markers of bone formation reflect endosteal bone loss in elderly men-MINOS study. Bone 36:13–21PubMedCrossRef

33.

Meier C, Nguyen TV, Center JR, Seibel MJ, Eisman JA (2005) Bone resorption and osteoporotic fractures in elderly men: the Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res 20:579–587PubMedCrossRef

34.

Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604–610PubMedCrossRef

35.

Sato Y, Iwamoto J, Kanoko T, Satoh K (2005) Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 165:1743–1748PubMedCrossRef

36.

Ringe JD, Faber H, Farahmand P, Dorst A (2005) Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 7:1–5

37.

Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP (2000) Therapy of idiopathic osteoporosis in men with parathyroid hormone: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85:3069–3076PubMedCrossRef

38.

Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman J-M, Clancy AD, Gaich GA (2003) The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Min Res 18:9–17CrossRef

39.

Kaufman J-M, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, Lindsay R, Mitlak BH (2005) Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int 16:510–516PubMedCrossRef

40.

Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216–1226PubMedCrossRef

41.

Kurland ES, Heller SL, Diamond B, McMahon DJ, Cosman F, Bilezikian JP (2004) The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1–34)]. Osteoporos Int 15:992–997PubMedCrossRef

42.

Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM, Bremner WJ, Tenover JL (2004) Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 89:503–510PubMedCrossRef

43.

Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, JSantanna J, Kapoor SC, Attie MF, Haddad JG Jr (1999) Strom BL Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84:1966–1972PubMedCrossRef

Title: Bone fragility in men - where are we?
Authors: E. Seeman
G. Bianchi
S. Khosla
J. A. Kanis
E. Orwoll
Publication date: 01-11-2006
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 11/2006
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-006-0160-8

At a glance: The STEP trials

Springer Medicine

Bone fragility in men - where are we?

Abstract

Introduction

Observations

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Observations

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2006

Minimum sample size requirements for bone density precision assessment produce inconsistency in clinical monitoring

Compliance with drug therapy for postmenopausal osteoporosis

Persistence with teriparatide in patients with osteoporosis: the UK experience

Young patients with hip fracture: a population-based study of bone mass and risk factors for osteoporosis

Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: a randomized double-blind controlled study

Racial disparity in treatment of osteoporosis after diagnosis